1. Home
  2. CMRE vs SRPT Comparison

CMRE vs SRPT Comparison

Compare CMRE & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Costamare Inc. $0.0001 par value

CMRE

Costamare Inc. $0.0001 par value

HOLD

Current Price

$14.03

Market Cap

1.9B

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$17.93

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMRE
SRPT
Founded
1974
1980
Country
Monaco
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2010
2000

Fundamental Metrics

Financial Performance
Metric
CMRE
SRPT
Price
$14.03
$17.93
Analyst Decision
Hold
Hold
Analyst Count
1
29
Target Price
$12.00
$25.85
AVG Volume (30 Days)
337.2K
3.0M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
3.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.99
Revenue
N/A
$2,198,237,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.55
$5.74
Revenue Growth
N/A
15.58
52 Week Low
$10.84
$14.68
52 Week High
$18.06
$25.32

Technical Indicators

Market Signals
Indicator
CMRE
SRPT
Relative Strength Index (RSI) 32.92 59.29
Support Level N/A $15.29
Resistance Level $17.76 $18.16
Average True Range (ATR) 0.49 0.80
MACD -0.13 0.24
Stochastic Oscillator 0.96 97.68

Price Performance

Historical Comparison
CMRE
SRPT

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: